Sheldon Shore, MD
Nephrology · Atlanta, GANPI 1588647697
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $375,978 of the $474,173 with a category attached, or 79.3%. 36 manufacturers reported payments, led by Bayer at 27.1% of the total. Among nephrology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,471 payments — averaging $322.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$129K
- AstraZeneca$118K
- Travere Therapeutics, Inc.$76K
- Otsuka America Pharmaceutical, Inc.$53K
- Lilly USA, LLC$28K
- Boehringer Ingelheim$15K
- plus $55K from 30 others
What the payments were for
- Consulting fees$44,9329%
- Speaking & faculty fees$375,97879%
- Travel & lodging$24,9475%
- Food & beverage$27,8216%
- Education$4940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$474,173 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 418 | $428,433 |
| JardianceEmpagliflozin | 163 | $152,284 |
| KerendiaFinerenone | 81 | $119,978 |
| OzempicSemaglutide | 102 | $119,083 |
| MounjaroTirzepatide | 36 | $53,701 |
| LokelmaSodium Zirconium Cyclosilicate | 41 | $37,835 |
| RayaldeeCalcifediol | 21 | $27,673 |
| JanuviaSitagliptin Phosphate | 13 | $17,650 |
| InvokanaCanagliflozin | 11 | $16,580 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 52 | $14,867 |
| VeltassaPatiromer Calcium Sorbitex | 14 | $14,653 |
| TrulicityDulaglutide | 12 | $11,787 |
| Clonidine | 52 | $9,672 |
| Eplerenone | 105 | $8,221 |
| DapagliflozinDapagliflozin Propanediol | 15 | $6,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $118,010 | $466,268459 claims |
| Boehringer IngelheimJardiance | $15,164 | $152,284163 claims |
| BayerKerendia | $128,534 | $119,97881 claims |
| Novo NordiskOzempic | $384 | $119,083102 claims |
| Lilly USA, LLCMounjaro, Trulicity | $28,146 | $65,48948 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $787 | $27,67321 claims |
| Johnson & JohnsonInvokana | $34 | $16,58011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 nephrology providers in Georgia.
Other nephrology in Atlanta
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Frederic Rahbari OskouiAtlanta$88K
- Tarik LalwaniAtlanta$69K
- Haimanot WasseAtlanta$60K
- Janice LeaAtlanta$21K
- Vandana NiyyarAtlanta$11K
- Gautham ViswanathanAtlanta$10K
- Lara WatkinsAtlanta$8K
- Saied MurphyAtlanta$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.